4月25日,国家药监局(NMPA)官网显示,诺诚健华的BTK抑制剂奥布替尼(商品名:宜诺凯)获批新适应症,用于一线治疗慢性淋巴细胞白血病(CLL)/小淋巴细胞淋巴瘤(SLL)患者(CLL/SLL)成人患者。至此,奥布替尼在国内已获批4项适应症,前3项适应症为:1)既往至少接受过一种治疗的复发或难治性CLL/SLL成人患者;2)既往至少接受过一种治疗的复发或难治性套细胞淋巴瘤(MCL)成人患者;3)...
Source Link4月25日,国家药监局(NMPA)官网显示,诺诚健华的BTK抑制剂奥布替尼(商品名:宜诺凯)获批新适应症,用于一线治疗慢性淋巴细胞白血病(CLL)/小淋巴细胞淋巴瘤(SLL)患者(CLL/SLL)成人患者。至此,奥布替尼在国内已获批4项适应症,前3项适应症为:1)既往至少接受过一种治疗的复发或难治性CLL/SLL成人患者;2)既往至少接受过一种治疗的复发或难治性套细胞淋巴瘤(MCL)成人患者;3)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.